EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting.

EfficAcy and safety of carboPlatin, etoposide and atezOlizumab for the first-line treatment of patients with extensive-stage smaLL cell lung cancer in the real-wOrld setting. - APOLLO study

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000038064

Enrollment

200

Registered

2019-09-24

Start date

2019-09-24

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Small cell lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Extensive-stage small cell lung cancer Patients scheduled for carboplatin / etoposide / atezolizumab combination therapy

Exclusion criteria

Exclusion criteria: Patients who are judged by the attending doctor as inappropriate to participate in this clinical research

Design outcomes

Primary

Measure	Time frame
6 months-PFS	—

Secondary

Measure	Time frame
Overall survival Progression free survival Time to treatment failure Objective response rate Safety(severe toxicity) The difference of clinical outcomes between eligible and ineligible patients for Impower 133 trial	—

Countries

Japan

Contacts

Public ContactDaichi Fujimoto

Kobe city medical center general hospital Division of Respiratory medicine

daichianzen@yahoo.co.jp078-302-4321

Outcome results